Cara Therapeutics Q3 2023 net loss $28M; cash runway extended into 2025 via $40M royalty financing

Tvardi Therapeutics, Inc.

2023-Q3 EPS reported -$1.59 revenue$17,964,000

Q3 total revenue $4.9M, down from $10.8M YoY; net loss $0.52/share vs $0.43/share YoY.
Cash $83.3M at Sep 30, 2023; entered $40M royalty financing with HealthCare Royalty to extend runway into 2025.
KORSUVA injection net sales $4.4M; vial orders up 36% QoQ; CMS confirmed TDAPA period until Mar 31, 2024.
Topline data from KIND 1 Phase 3 atopic dermatitis expected Dec 2023; KICK Phase 3 results in 2H24.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Tvardi Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $4.9 million, net income $28.0 million, or $(0.52) per basic and diluted share, EPS $(0.52) per basic and diluted share.

Period: third quarter ended September 30, 2023
Revenue: $4.9 million
Net income: $28.0 million, or $(0.52) per basic and diluted share
EPS: $(0.52) per basic and diluted share
Result: reported results

Exact text from the filing

For the third quarter of 2023, net loss was $28.0 million, or $(0.52) per basic and diluted share, compared to net loss of $23.2 million, or $(0.43) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $4.9 million and $10.8 million for the three months ended September 30, 2023 and 2022, respectively.

View on SEC.gov

Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-117212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.